statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
AS - Asia	2.528
NA - Nord America	2.012
EU - Europa	956
SA - Sud America	438
AF - Africa	38
OC - Oceania	2
Totale	5.974

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1.917
SG - Singapore	1.501
HK - Hong Kong	537
BR - Brasile	387
CN - Cina	280
IT - Italia	239
GB - Regno Unito	231
RU - Federazione Russa	231
DE - Germania	81
VN - Vietnam	55
MX - Messico	50
CA - Canada	34
IN - India	30
FI - Finlandia	24
SE - Svezia	23
TR - Turchia	23
ZA - Sudafrica	22
AT - Austria	21
AR - Argentina	20
JP - Giappone	20
BD - Bangladesh	19
IQ - Iraq	17
NL - Olanda	16
ES - Italia	14
IE - Irlanda	13
FR - Francia	12
LT - Lituania	11
PL - Polonia	11
CO - Colombia	8
SA - Arabia Saudita	8
UA - Ucraina	8
UZ - Uzbekistan	8
CH - Svizzera	7
CL - Cile	6
EC - Ecuador	6
KE - Kenya	6
EE - Estonia	5
PK - Pakistan	5
VE - Venezuela	5
AE - Emirati Arabi Uniti	4
NP - Nepal	4
BE - Belgio	3
HN - Honduras	3
IR - Iran	3
AU - Australia	2
BO - Bolivia	2
CZ - Repubblica Ceca	2
ID - Indonesia	2
JO - Giordania	2
KG - Kirghizistan	2
LB - Libano	2
MA - Marocco	2
NI - Nicaragua	2
PE - Perù	2
TN - Tunisia	2
TT - Trinidad e Tobago	2
AM - Armenia	1
BB - Barbados	1
BH - Bahrain	1
CI - Costa d'Avorio	1
CR - Costa Rica	1
DK - Danimarca	1
EG - Egitto	1
ET - Etiopia	1
GT - Guatemala	1
HU - Ungheria	1
IL - Israele	1
JM - Giamaica	1
LY - Libia	1
MD - Moldavia	1
MY - Malesia	1
NG - Nigeria	1
PT - Portogallo	1
PY - Paraguay	1
QA - Qatar	1
SN - Senegal	1
TL - Timor Orientale	1
UY - Uruguay	1
Totale	5.974

Salva come PNG Salva come JPEG

Città	#
Singapore	888
Hong Kong	533
Dallas	287
Chicago	255
Boardman	236
London	184
Beijing	156
Ashburn	110
The Dalles	101
Los Angeles	61
Santa Clara	60
Mexico City	40
São Paulo	40
Munich	28
New York	28
Assago	26
Nuremberg	24
Brooklyn	22
Ho Chi Minh City	19
Stockholm	19
Tokyo	19
Milan	18
San Francisco	18
Johannesburg	17
Salt Lake City	16
Ankara	14
Frankfurt am Main	14
Turku	14
Denver	13
Dublin	13
Hanoi	13
Atlanta	12
Boston	12
Belo Horizonte	11
Chennai	11
Manchester	10
Rio de Janeiro	10
Warsaw	10
Flanders	9
Houston	9
Orem	9
Poplar	9
Toronto	9
Vergiate	9
Chandler	8
Düsseldorf	8
Helsinki	8
Montreal	8
Moscow	8
Phoenix	8
Rome	8
Tashkent	8
Vienna	8
Buffalo	7
Porto Alegre	7
Amsterdam	6
Baghdad	6
Cavaria con Premezzo	6
Contagem	6
Fairfield	6
Indianapolis	6
Nairobi	6
Piracicaba	6
Romola	6
Seattle	6
Secaucus	6
São José dos Campos	6
Brasília	5
Campinas	5
Campo Grande	5
Erbil	5
Guidonia Montecelio	5
Jacksonville	5
Ottawa	5
Salvador	5
Sterling	5
Varese	5
Charlotte	4
Detroit	4
Fort Worth	4
Fortaleza	4
Goiânia	4
Haiphong	4
Joinville	4
Juiz de Fora	4
Kansas City	4
Miami	4
Riyadh	4
Anápolis	3
Brussels	3
Caruaru	3
Curitiba	3
Des Moines	3
Dhaka	3
Durban	3
Guarulhos	3
Guayaquil	3
Jeddah	3
New Delhi	3
Nyköping	3
Totale	3.704

Salva come PNG Salva come JPEG

Nome	#
AISF position paper on HCV in immunocompromised patients	136
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	48
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	47
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	45
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	45
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	44
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	43
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	43
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	43
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	42
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	42
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	42
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	41
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	40
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	39
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	38
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	38
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	37
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	37
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	37
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	37
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	36
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	36
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	36
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	36
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	35
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	35
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	34
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	34
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	34
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	34
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	34
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	34
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	33
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	32
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	32
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	32
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	31
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	31
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	31
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells	31
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	31
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	31
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	31
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance	31
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	31
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	31
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	30
Longitudinal Assessment of CLL Patients Under Ibrutinib Treatment Reveals Maintained Capacity to Respond to Microenvironmental Stimuli through the Toll-like Receptors	30
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	30
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	30
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results	30
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	30
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	30
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	30
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	30
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL)	29
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	29
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	29
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	29
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	29
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	29
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	29
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	28
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells	28
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	28
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)	28
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	28
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL	28
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	28
OXIDATIVE STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA	28
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance	28
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	28
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells	28
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	28
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	28
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	27
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	27
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma	27
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	27
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	27
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	27
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	27
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study	27
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation	27
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	27
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism	27
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL	27
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	27
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	27
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL	27
Effective anti-tumor immunomodulatory properties of zoledronic acid in Balb/c mice transgenic for the her-2/Neu oncogene	27
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	27
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	26
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy	26
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	26
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience	26
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study	26
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	26
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	26
Totale	3.299

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	41.954
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	41.954

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	15	0	0	0	0	0	2	0	4	2	2	1	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	2.691	411	465	436	846	458	75	0	0	0	0	0	0
Totale													6.215